Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 452-461

  Toi, Hirofumi ^a,b   Tsujie, Masanori ^a,c   Haruta, Yuro ^a,d   Fujita, Kanako ^a   Duzen, Jill ^a   Seon, Ben K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Megumino Hospital   (Japan)

^c KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^d Matsuonaika Hospital   (Japan)

Author keywords

antiendoglin monoclonal antibodies; genetically engineered mouse model; humanized endoglin; synergy; vascular targeting cancer therapy

Indexed keywords

CAPECITABINE; ENDOGLIN; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SN6C; MONOCLONAL ANTIBODY SN6J; SORAFENIB; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENG GENE; EXON; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; GENOTYPE; HOMOZYGOSITY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; C57BL MOUSE; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SOUTHERN BLOTTING; TRANSGENIC MOUSE; TUMOR CELL CULTURE; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APOPTOSIS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED;

EID: 84921742499     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28994     Document Type: Article

References (46)

1. Ebos JM, Kerbel RS,. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210-21.
2. Moreno Garcia V, Basu B, Molife LR, et al., Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012; 18: 3750-61.
3. Jayson GC, Hicklin DJ, Ellis LM,. Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol 2012; 9: 297-303.
4. Seon BK, Matsuno F, Haruta Y, et al., Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997; 3: 1031-44.
5. Matsuno F, Haruta Y, Kondo M, et al., Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5: 371-82.
6. Takahashi N, Haba A, Matsuno F, et al., Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001; 61: 7846-54.
7. Tsujie M, Tsujie T, Toi H, et al., Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 2008; 122: 2266-73.
8. Uneda S, Toi H, Tsujie T, et al., Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009; 125: 1446-53.
9. Cheifetz S, Bellon T, Cales C, et al., Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-30.
10. Nolan-Stevaux O, Zhong W, Culp S, et al., Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS One 2012; 7: e50920.
11. Burrows FJ, Derbyshire EJ, Tazzari PL, et al., Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623-34.
12. Miller DW, Graulich W, Karges B, et al., Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999; 81: 568-72.
13. Seon BK, Haba A, Matsuno F, et al., Endoglin-targeted cancer therapy. Curr Drug Deliv 2011; 8: 135-43.
14. Clasper S, Royston D, Baban D, et al., A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res 2008; 68: 7293-303.
15. Li DY, Sorensen LK, Brooke BS, et al., Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534-7.
16. Arthur HM, Ure J, Smith AJ, et al., Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000; 217: 42-53.
17. Sanchez-Elsner T, Botella LM, Velasco B, et al., Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277: 43799-808.
18. Bockhorn M, Tsuzuki Y, Xu L, et al., Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 2003; 9: 4221-6.
19. Lebrin F, Goumans MJ, Jonker L, et al., Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23: 4018-28.
20. Haruta Y, Seon BK., Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci U S A 1986; 83: 7898-902.
21. Hong H, Yang Y, Zhang Y, et al., Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 2011; 38: 1335-43.
22. She X, Matsuno F, Harada N, et al., Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 2004; 108: 251-7.
23. Shiozaki K, Harada N, Greco WR, et al., Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother 2006; 55: 140-50.
24. Rosen LS, Hurwitz HI, Wong MK, et al., A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 2012; 18: 4820-9.
25. Wilhelm S, Carter C, Lynch M, et al., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
26. Takahashi N, Kawanishi-Tabata R, Haba A, et al., Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001; 7: 524-32.
27. Dinkel A, Aicher WK, Warnatz K, et al., Efficient generation of transgenic BALB/c mice using BALB/c embryonic stem cells. J Immunol Methods 1999; 223: 255-60.
28. Osoegawa K, Mammoser AG, Wu C, et al., A bacterial artificial chromosome library for sequencing the complete human genome. Genome Res 2001; 11: 483-96.
29. Lee EC, Yu D, Martinez de Velasco J, et al., A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 2001; 73: 56-65.
30. Osoegawa K, Tateno M, Woon PY, et al., Bacterial artificial chromosome libraries for mouse sequencing and functional analysis. Genome Res 2000; 10: 116-28.
31. Noben-Trauth N, Kohler G, Burki K, et al., Efficient targeting of the IL-4 gene in a BALB/c embryonic stem cell line. Transgenic Res 1996; 5: 487-91.
32. Schwenk F, Baron U, Rajewsky K,. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 1995; 23: 5080-1.
33. Collins TJ,. ImageJ for microscopy. Biotechniques 2007; 43(1 Suppl): 25-30.
34. She X, Seon BK., Epitope mapping of endoglin, a TGF-β receptor, using recombinant fragments and twelve monoclonal antibodies. Proc Am Assoc Cancer Res 2001; 42: 825.
35. Yokoyama Y, Dhanabal M, Griffioen AW, et al., Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000; 60: 2190-6.
36. Aguirre-Ghiso JA,. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-46.
37. Uhr JW, Pantel K., Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011; 108: 12396-400.
38. Ghajar CM, Peinado H, Mori H, et al., The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15: 807-17.
39. Volkel T, Holig P, Merdan T, et al., Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004; 1663: 158-66.
40. Munoz R, Arias Y, Ferreras JM, et al., Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b. Cancer Lett 2007; 256: 73-80.
41. Dolinsek T, Markelc B, Sersa G, et al., Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth. PLoS One 2013; 8: e58723.
42. McDonald J, Bayrak-Toydemir P, Pyeritz RE,. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med 2011; 13: 607-16.
43. Allinson KR, Carvalho RL, van den Brink S, et al., Generation of a floxed allele of the mouse Endoglin gene. Genesis 2007; 45: 391-5.
44. Levine EG, Forero A, O'Connor T, et al., A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent Her-2-negative metastatic breast cancer). J Clin Oncol 2013; 31:15S, 187s (2013 ASCO Annual Meeting Proceedings).
45. Anderberg C, Cunha SI, Zhai Z, et al., Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 2013; 210: 563-79.
46. Ardelean DS, Jerkic M, Yin M, et al., Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. Angiogenesis 2014; 17: 129-46.